| Title | Author(s) | Year | View Count |
 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | Liaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV | 2009 | 1,823 |
 | Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients | Hsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P | 2009 | 301 |
 | Errata: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | Liaw, YF; Leung, N; Kao, JH; Piratvisuth, T; Gane, E; Han, KH; Guan, R; Lau, GKK; Locarnini, S; The Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver | 2008 | 121 |
| The authors reply | Lai, CL; Gane, E; Brown, NA | 2008 | 45 |
| Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Schiff, E; Lai, CL; Hadziyannis, S; Nuehaus, P; Terrault, N; Colombo, M; Tillmann, H; Samuel, D; Zuezem, S; Villenueve, JP; Arteburn, S; BorrotoEsoda, K; Brosgart, C; Chuck, S; Shakil, AO; Fung, J; Alberti, A; Lok, A; Picciotto, A; Torre, F; Riely, C; Trepo, C; Bizollon, T; BottaaFridlund, D; Gerolami, R; Douglas, D; Ranjan, D; Faust, D; Trojan, J; Gane, E; Villa, E; Boarino, M; Sokal, E; Starkel, P; Bonino, F; Maurizio, B; Gordon, F; Pratt, J; Berr, F; Schiefke, I; McCaughan, G; Strasser, S; Dusheiko, G; Pageaux, GP; Larrey, D; Pastore, G; Santantonio, T; Alexander, G; Woodall, T; Van Vlierberghe, H; Colle, I; Harley, H; Guggenheim, J; MyxStaccini, A; Metreau, JM; Mavier, P; Vierling, J; Tran, T; Girgrah, N; Nyberg, L; Yuen, MF; Ma, M; Balnco, MD; Merli, M; Tanzilli, P; Angelico, M; Di Paolo, D; Rizzetto, M; Marzano, A; Lampertico, P; Prieto, M; Berenguer, M; Felder, M; Sterneck, M; Willems, M; Charlton, M; Gunneson, T; Ritter, M; Voight, M; Swift, J; Shiffman, M; Tassopoulos, N; Klissas, I; Naourmov, N; Chamouard, P; Marcellin, P; Durand, F; Angus, P; Nathan, C; Toniutto, P; Fumo, E; Andreone, P; Cursaro, C; Barcena, R; Hoz, FG; Zachoval, R; Christina, M; De Man, RA; Metselaar, H | 2007 | 140 |
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA | 2007 | 245 |
| Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelines | Rasenack, J; Poynard, T; Lai, CL; Gane, E; Brown, NA; Heathcote, J | 2007 | 144 |
| Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response | Lai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA | 2007 | 108 |
| Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study | Thongsawat, S; Lai, CL; Gane, E; Chao, G; Fielman, B; Brown, N; GLOBE Investigator Group, . | 2006 | 130 |
| Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B | Naoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N | 2006 | 101 |
| Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine | Lai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE., | 2006 | 187 |
| Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients | Zeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 116 |
| Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients | DiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE, | 2006 | 158 |
| Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year | Gane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 120 |
| Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year | Bzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 116 |
| Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 153 |
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B | Lau, GK; Piratvisuth, T; Luo, KX; Marcellin, P; Thongsawat, S; Cooksley, G; Gane, E; Fried, MW; Chow, WC; Paik, SW; Chang, WY; Berg, T; Flisiak, R; McCloud, P; Pluck, N | 2005 | 378 |
| Improved Survival with Screening for Hepatocellular Carcinoma in Chronic Hepatitis B and Liver Cirrhosis | Fung, JYY; Gane, E; McCall, J; Holden, A | 2005 | 97 |
| Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 151 |
| Practical Difficulties in the Management of Hepatitis B in the Asia-Pacific Region | Mohamed, R; Desmond, P; Suh, DJ; Amarapurkar, D; Gane, E; Guangbi, Y; Hou, JL; Jafri, W; Lai, CL; Lee, CH; Lee, SD; Lim, SG; Guan, R; Phiet, PH; Piratvisuth, T; Sollano, J; Wu, JC | 2004 | 115 |
|
